• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing

Responding to a Subscriber Question About Immunomedics

What does the upside or the downside look like?
By BRUCE KAMICH
Dec 30, 2019 | 10:36 AM EST
Stocks quotes in this article: IMMU

Readers of Real Money sometimes email me with questions about stocks they are interested in. Time permitting, I make an effort to respond to all emails. Most of the time I just respond to the subscriber but sometimes the stock catches my attention. One subscriber asked about what I thought of Immunomedics (IMMU) . The company is a  clinical-stage biopharmaceutical company that is "developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases".

Let's check out the charts of this cutting edge company to see what the upside or the downside looks like. 

In this daily bar chart of IMMU, below, we can see three tests of the $12 area over the past year. Each time prices got down to around the $12 area - January, June, and October - buyers entered and lifted prices. Since the low in October prices have rallied to make a new high for the year.
 
IMMU is above the rising 50-day moving average line and above the rising 200-day line. In early November we can see a bullish golden cross of the 50-day line and the slower-to-react 200-day line. This math-driven buy signal is typically late but it can be effective in long-trending markets.
 
The Moving Average Convergence Divergence (MACD) oscillator is above the zero line and in a bullish configuration.  
 
 
In this weekly bar chart of IMMU, below, we can see a strong rally from 2017 to 2018 taking prices from around $4 to over $26 before a correction down to around $12. A new base has formed from around $12 and now prices have firmed back to the underside of the $22-$27 top area. Prices are above the rising 40-week moving average line.
 
The weekly OBV line has been strong in recent months and is at a new high for the move up - a bullish set-up and confirms the price gains this year.
 
The weekly MACD oscillator moved above the zero line in late October for an outright go long signal which continues today.  
 
 
 
In this Point and Figure chart of IMMU, below, we can see a potential longer-term price target of $40.50 being projected. A trade at $28 will be a fresh breakout on this chart. 
 
Bottom line strategy: Aggressive traders could go long IMMU in the $22-$21 area risking a close below $17 for now. $40 is our longer-term price target.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals

More from Investing

Fossil Group Sounds the Alarm While NL Industries Rewards Its Shareholders

Jonathan Heller
Aug 12, 2022 10:30 AM EDT

The former signaled lower revenues for the year while the latter declared a healthy special dividend.

The TJX Companies Reports Next Week, But There's a Trade Here

Stephen Guilfoyle
Aug 12, 2022 10:15 AM EDT

Many large chain retailers report during the week to round out earnings season, along with the July Retail Sales.

Major Indexes Keep Uptrends Intact After Mixed Thursday

Guy Ortmann
Aug 12, 2022 10:00 AM EDT

However, we are becoming more reticent about chasing price at current levels given some of the data and valuation issues.

Could China Be Our Next Move?

Bruce Kamich
Aug 12, 2022 9:00 AM EDT

Here's what I see with the iShares China Large-Cap ETF.

If You're Buying the Dips in QQQ, Here Are 2 Zones to Consider

Bob Byrne
Aug 12, 2022 8:30 AM EDT

There are a pair of moving averages to watch in this process.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login